drugset / Trial / NCT05313022
Safety and Immunogenicity of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19
Phase 1/2
Unknown
84 enrolled
Shanghai Zerun Biotechnology Co.,Ltd
Walvax Biotechnology Co., Ltd. · collab
RandomizedParallel-groupTriple-blindPrevention
Summary
The purpose of this double-blind, randomized, controlled study is to assess safety, reactogenicity, and immunogenicity of ZR-202-CoV, administered as 2 injections (i.m) at 28 days apart in adult subjects 60 years of age and above.
Timeline
- Start
- 2022-01-18
- Primary completion
- 2022-05-13
- Completion
- 2023-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ZR202-CoV | Vaccine | — | Intramuscular |